Elmiron (pentosan polysulfate sodium, or PPS) was approved by the FDA way back in September 1996 for the treatment of painful bladder syndrome (interstitial cystitis). Over the past several years, however, cases of Elmiron-related eye damage have been reported. Remarkably, according to a recent … More
Main Navigation Menu
➤ Pharmaceutical Drug Injury Lawsuits
➤ Asbestos and Mesothelioma Claims
➤ Benzene Diseases and Cancers Claims
➤ GenX Water Contamination Cancer Cases
➤ Breast Implants Lymphoma Cancer Cases
➤ Free Case Evaluation by Lawyer Tom Lamb
➤ About the Law Offices of Thomas J. Lamb
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Collection of Articles by Our Law Firm
Please know that you can use our Quick Contact Form to tell us a bit about your case.
Recent Articles
Study seeks to identify biological markers that predict mesothelioma response to treatment
The National Cancer Institute (NCI) has granted a $2.5 million, five-year R37 MERIT Award to Dr. Bryan Burt, associate professor of surgery and chief of the Division of General Thoracic Surgery, for his [ mesothelioma medical study ] titled, “Proteomic Determinants of Response to Checkpoint Blockade … More
New Xeljanz Warnings From FDA in 2021; Are Other JAK Inhibitors Next?
After the January 2021 release of limited data from a Xeljanz safety trial which often goes by its short name, ORAL Surveillance, some experts raised the possibility that there may consequences for other drugs in the Janus kinase (JAK) inhibitors class of drugs. Specifically, some have asked whether … More
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Background: Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including first-line non-small-cell … More
Xeljanz 2021 FDA Warnings: Xeljanz Causing Heart Problems and Xeljanz Causing Cancer
The Xeljanz safety issues of Xeljanz causing heart problems and Xeljanz causing cancer were already "highlighted" by means of the Xeljanz Black Box Warning added back in 2019. But in February 2021 the FDA pointed out these Xeljanz side effects again in this FDA Drug Safety Communication, "Initial … More
New Options Spark Sequencing and Biomarker Trials in Mesothelioma
Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual … More